News

Florence, Jan. 26, 2024 – PQE Group, the renowned Life Science consulting powerhouse, concludes the fiscal year 2023 with a 10% growth and an upwardly revised income exceeding 100 million euros in revenues. The Italian headquartered global firm, celebrated as a preferred advisor to pharma manufacturing and medical device corporations and SMEs globally, marks this success as a testament to its resilience, adaptability, and strategic vision amid the complex global landscape.

“At a time when many companies grapple with geopolitical challenges, crises, and inflation rates, PQE Group stands out not only for its resilience but for its ability to thrive in uncertain times, showcasing positive growth across all financial indicators,” stated Gilda D’Incerti, CEO & Founder of PQE Group. “This success is rooted in meticulous planning, strategic investments in cutting-edge technologies, and a corporate culture that values agility and innovation.”

ROCKVILLE, Md., Jan. 29, 2024 /PRNewswire/ — Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has enrolled its first patient in its R-2487 Phase 1 rheumatoid arthritis clinical trial.

“This is an important milestone for the company and patients suffering from rheumatoid arthritis” states Gary Fanger President and Chief Executive Officer of Rise Therapeutics. “This achievement reinforces our commitment to deliver innovative new medicines to the clinical community.”

Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.

The university-industry partnership will serve as a beacon for this field by investigating research opportunities that address challenges and research gaps facing the microbiome, which involves the research into a community of microorganisms that can be found living together in any given environment, including the human body.

ROCKVILLE, Md., and SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Imugene, (ASX: IMU), a clinical-stage immuno-oncology and cell therapy company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors, today announced the signing of a strategic platform license (SPL).

Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.

After a period of leadership transition and strategic planning, the organizations behind one of Baltimore’s longest-standing entrepreneurial communities have appointed a new executive director to take it to the next level.

On Tuesday, the Baltimore Development Corporation (BDC) and Maryland Technology Development Corporation (TEDCO) jointly announced the appointment of Arti Santhanam as the new executive director of the Emerging Technology Centers (ETC Baltimore).

Santhanam most recently served as executive director of TEDCO’s Maryland Innovation Initiative (MII), a public-private effort to promote academic research commercialization across the state.

BALTIMORE, Jan. 22, 2024 /PRNewswire/ — Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus’ SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist. SD-101 is delivered via hepatic arterial infusion or pancreatic retrograde venous infusion in their phase 1 and 1b clinical trials using their proprietary Pressure-Enabled Drug Delivery™ (PEDD™) to overcome the challenges associated with intratumoral pressure for patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma.

January 16, 2024  –  By Laura Lee – Principal Investigator Robert K. Ernst, PhD, the Dr. Paul and Mrs. Jean Corcoran Endowed Professor and chair of the Department of Microbial Pathogenesis at the University of Maryland School of Dentistry (UMSOD) and Distinguished University Professor, has been awarded a five-year, $9.4 million contract from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to continue work developing and testing novel adjuvants for the improvement of vaccines. Ernst was awarded $6.4 million in funding through the same NIAID program in 2018, bringing his total funding for adjuvant development to over $16 million.

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These four collaborative projects, involving Virginia research universities and industry partners, were awarded through Virginia Catalyst Grant Round 15 to address major unmet healthcare needs and drive job creation and capital formation in Virginia.

Through this 15^th round of funding, Virginia Catalyst has awarded 61 grants totaling $29.7 million, resulting in over $47 million in matching funds and an additional $821 million in follow-on funding to date.